Controlled-release pregabalin in the treatment of fibromyalgia

References

• Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med. 2004;66:837–844.
   PubMed Web of Science ®Google Scholar
• Raphael KG, Janal MN, Nayak S, et al. Psychiatric comorbidities in a community sample of women with fibromyalgia. Pain. 2006;124(1–2):117–125.
   PubMed Web of Science ®Google Scholar
• Uguz F, Cicek E, Salli A, et al. Axis I and Axis II psychiatric disorders in patients with fibromyalgia. Gen Hosp Psychiatry. 2010;32(1):105–107.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160–172.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62(5):600–610.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113–1122.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles MA, et al. Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–329.
   PubMed Web of Science ®Google Scholar
• Jones GT, Atzeni F, Beasley M, et al. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheum. 2015;67(2):568–575.
   PubMed Web of Science ®Google Scholar
• Bradley LA. Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatry. 2008;69(Suppl 2):6–13.
   PubMed Web of Science ®Google Scholar
• Buskila D, Sarzi-Puttini P. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther. 2006;8(5):218.
   PubMed Web of Science ®Google Scholar
• Yavne Y, Amital D, Watad A, et al. A systematic review of precipitating physical and psychological traumatic events in the development of fibromyalgia. Semin Arthritis Them. 2018;48(1):121-133.
   Google Scholar
• Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states–maybe it is all in their head. Best Pract Res Clin Rheum. 2011;25(2):141–154.
   PubMed Web of Science ®Google Scholar
• Annemans L, Le Lay K, Taieb C. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics. 2009;27:547–559.
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA, Da Costa D, Poyhia R. A study of standard care in fibromyalgia syndrome: a favorable outcome. J Rheum. 2003;30(1):154–159.
   PubMed Web of Science ®Google Scholar
• White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med. 2008;50(1):13–24.
   PubMed Web of Science ®Google Scholar
• McDonald M, DiBonaventura M, Ullman S. Musculoskeletal pain in the workforce: the effects of back, arthritis, and fibromyalgia pain on quality of life and work productivity. J Occup Environ Med. 2011;53(7):765–770.
   PubMed Web of Science ®Google Scholar
• Rao SG, Gendreau JF, Kranzler JD. Understanding the fibromyalgia syndrome. Psychopharmacol Bull. 2007;40:24–67.
   PubMedGoogle Scholar
• Harris RE, Clauw DJ, Scott DJ, et al. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27(37):10000–10006.
   PubMed Web of Science ®Google Scholar
• Younger J, Noor N, McCue R, et al. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538.
   PubMed Web of Science ®Google Scholar
• Hauser W, Petzke F, Uceyler N, et al. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology. 2011;50(3):532–543.
   PubMed Web of Science ®Google Scholar
• Hauser W, Wolfe F, Tolle T, et al. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26(4):297–307.
   PubMed Web of Science ®Google Scholar
• Hauser W, Urrutia G, Tort S, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2013;31(1):CD010292.
   Google Scholar
• Dworkin RH, Kirkpatrick P. Pregabalin. Nat Rev Drug Discov. 2005;4(6):455–456.
   PubMed Web of Science ®Google Scholar
• Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adher. 2013;7:419–434.
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007 Feb;28(2):75–82.
   PubMed Web of Science ®Google Scholar
• Bian F, Li Z, Offord J, et al. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 2006;1075(1):68–80.
   PubMedGoogle Scholar
• Su TZ, Feng MR, Weber ML. Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther. 2005;313(3):1406–1415.
   PubMed Web of Science ®Google Scholar
• Chew ML, Alvey CW, Plotka A, et al. Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. Clin Drug Investig. 2014;34(9):627–637.
   PubMed Web of Science ®Google Scholar
• Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277–283.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46(9):1407–1413.
   PubMed Web of Science ®Google Scholar
• Winterfeld U, Merlob P, Baud D, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology. 2016;86(24):2251–2257.
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264–1273.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35(3):502–514.
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419–431.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9(9):792–805.
   PubMed Web of Science ®Google Scholar
• Pauer L, Winkelmann A, Arsenault P, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011;38(12):2643–2652.
   PubMed Web of Science ®Google Scholar
• Ohta H, Oka H, Usui C, et al. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arth Res Ther. 2012;14(5):R217.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Arsenault P, Huffman C, et al. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr Med Res Opin. 2014;30(10):2069–2083.
   PubMed Web of Science ®Google Scholar
• Gerardi MC, Atzeni F, Batticciotto A, et al. The safety of pregabalin in the treatment of fibromyalgia. Expert Opin Drug Saf. 2016;1–8.
   PubMedGoogle Scholar
• Uceyler N, Sommer C, Walitt B, et al. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev. 2013;16(10):CD010782.
   Google Scholar
• Zhao Y, Sun P, Watson P, et al. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2011;11(3):204–216.
   PubMed Web of Science ®Google Scholar
• Marlow NM, Simpson KN, Vaughn IA, et al. Healthcare costs and medication adherence among patients with fibromyalgia: combination medication vs. duloxetine, milnacipran, venlafaxine, and pregabalin initiators. Pain Pract. 2018;18(2):154–169.
   PubMed Web of Science ®Google Scholar
• Sun P, Peng X, Sun S, et al. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators. Pain Pract. 2014;14(1):22–31.
   PubMed Web of Science ®Google Scholar